{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:53:33Z","timestamp":1761580413736},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.juro.2006.03.068","type":"journal-article","created":{"date-parts":[[2006,6,29]],"date-time":"2006-06-29T17:44:54Z","timestamp":1151603094000},"page":"548-553","source":"Crossref","is-referenced-by-count":11,"title":["Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024"],"prefix":"10.1097","volume":"176","author":[{"given":"Gregory P.","family":"Swanson","sequence":"first","affiliation":[{"name":"University of Texas Health Science Center, San Antonio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Faulkner","sequence":"additional","affiliation":[{"name":"Brook Army Medical Center\/Wilford Hall Medical Center, San Antonio"},{"name":"Southwest Oncology Group Statistical Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Smalley","sequence":"additional","affiliation":[{"name":"Kansas City Community Clinical Oncology Program, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Noble","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald L.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Kansas City Community Clinical Oncology Program, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"O\u2019Rourke","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio"},{"name":"Brook Army Medical Center\/Wilford Hall Medical Center, San Antonio"},{"name":"JACC Covenant Health Systems, Lubbock, Texas"},{"name":"Southwest Oncology Group Statistical Center, Seattle, Washington"},{"name":"Kansas City Community Clinical Oncology Program, Kansas City, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey R.","family":"Weiss","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Quick","sequence":"additional","affiliation":[{"name":"JACC Covenant Health Systems, Lubbock, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[{"name":"University of Colorado Health Science Center, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2006.03.068_bib1","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/1097-0142(19931201)72:11<3156::AID-CNCR2820721106>3.0.CO;2-G","article-title":"Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy","volume":"72","author":"Perez","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.03.068_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0360-3016(93)90273-X","article-title":"Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate","volume":"26","author":"Perez","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib3","first-page":"47","article-title":"Status of radiation treatment of prostate cancer at Stanford University","volume":"7","author":"Bagshaw","year":"1988","journal-title":"Mongr Natl Ca Inst"},{"key":"10.1016\/j.juro.2006.03.068_bib4","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/1097-0142(19950501)75:9<2373::AID-CNCR2820750930>3.0.CO;2-2","article-title":"Potential benefit of improved local tumor control in patients with prostate carcinoma","volume":"75","author":"Kuban","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.03.068_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0360-3016(95)00154-Q","article-title":"Prostate cancer and radiation therapy\u2014the message conveyed by serum prostate-specific antigen","volume":"33","author":"Zagars","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2003.10.026","article-title":"Long term follow-up of radiotherapy for prostate cancer","volume":"59","author":"Swanson","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(69)90783-1","article-title":"Fluorouracil and radiotherapy in gastrointestinal cancer","volume":"2","author":"Falkson","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2006.03.068_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0360-3016(91)90091-H","article-title":"5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells","volume":"20","author":"Smalley","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0360-3016(90)90764-B","article-title":"Heterogeneity of 5-Flurouracil radiosensitivity modulation in cultured mammalian cell lines","volume":"18","author":"Smalley","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.juro.2006.03.068_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0360-3016(95)00123-G","article-title":"The treatment of prostate cancer by conventional radiation therapy","volume":"32","author":"Zeitman","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0360-3016(83)90287-0","article-title":"Do prostate biopsies 12 months or more after external irradiation for adenocarcinoma, stage III, predict long term survival?","volume":"9","author":"Cox","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/0360-3016(86)90311-1","article-title":"Current conflicts in the management of prostate cancer","volume":"12","author":"Bagshaw","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(00)00637-4","article-title":"Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients","volume":"48","author":"Crook","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of he prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","article-title":"Updated results of the phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate","volume":"49","author":"Lawton","year":"2001","journal-title":"Int Jrl Radiat Oncol Biol Phys"},{"key":"10.1016\/j.juro.2006.03.068_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study)","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2006.03.068_bib18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2004.03.006","article-title":"Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high risk localized prostate cancer","volume":"64","author":"Ryan","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.03.068_bib19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.2004.02.001","article-title":"Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2006.03.068_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2006.03.068_bib21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706008238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706008238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2006.03.068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:14:46Z","timestamp":1651194886000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2006.03.068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1016\/j.juro.2006.03.068"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2006.03.068","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}